UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families

Breast cancer research and treatment, 2011-10, Vol.129 (3), p.939-946

2011

Volltextzugriff (PDF)

Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy

Clinical cancer research, 2024-05, Vol.30 (10), p.2160-2169

2024

Volltextzugriff (PDF)

Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial

Breast cancer research and treatment, 2016-04, Vol.156 (3), p.507-515

2016

Volltextzugriff (PDF)

A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study

Investigational new drugs, 2019-02, Vol.37 (1), p.98-108

2019

Volltextzugriff (PDF)

Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine‐Induced Hand‐Foot Syndrome

Clinical pharmacology and therapeutics, 2021-02, Vol.109 (2), p.462-470

2021

Volltextzugriff (PDF)

Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3

The oncologist (Dayton, Ohio), 2021-03, Vol.26 (3), p.e522-e522

2021

Volltextzugriff (PDF)

Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor

Clinical cancer research, 2022-03, Vol.28 (6), p.1107-1116

2022

Volltextzugriff (PDF)

XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease

Breast cancer research : BCR, 2023-06, Vol.25 (1), p.67-67, Article 67

2023

Volltextzugriff (PDF)

Adoptive Cell Therapy in Breast Cancer: A Current Perspective of Next-Generation Medicine

Frontiers in oncology, 2020-10, Vol.10, p.605633-605633

2020

Volltextzugriff (PDF)

Chemotherapy for gastric cancer

World journal of gastroenterology : WJG, 2006-01, Vol.12 (2), p.204

2006

Volltextzugriff (PDF)

A Polymorphism in the Cytidine Deaminase Promoter Predicts Severe Capecitabine-Induced Hand-Foot Syndrome

Clinical cancer research, 2011-04, Vol.17 (7), p.2006-2013

2011

Volltextzugriff (PDF)

Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations

The oncologist (Dayton, Ohio), 2009-01, Vol.14 (1), p.1-11

2009

Volltextzugriff (PDF)

Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel: a study in locally advanced breast cancer patients participating in the NCT00123929 phase 2 randomized trial

Pharmacogenetics and genomics, 2018-11, Vol.28 (11), p.245-250

2018

Volltextzugriff (PDF)

CREditing: a tool for gene tuning in Trypanosoma cruzi

International journal for parasitology, 2020-11, Vol.50 (13), p.1067-1077

2020

Volltextzugriff (PDF)

Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients

Breast cancer research and treatment, 2018, Vol.167 (1), p.249-256

2018

Volltextzugriff (PDF)

Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial

Frontiers in oncology, 2022-09, Vol.12, p.886831-886831

2022

Volltextzugriff (PDF)

Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia

Breast (Edinburgh), 2020-12, Vol.54, p.160-163

2020

Volltextzugriff (PDF)

Effective gene delivery to Trypanosoma cruzi epimastigotes through nucleofection

Parasitology international, 2017-06, Vol.66 (3), p.236-239

2017

Volltextzugriff (PDF)

Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study

Breast cancer research and treatment, 2014-02, Vol.143 (3), p.507-515

2014

Volltextzugriff (PDF)

Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors

International journal of molecular sciences, 2023-07, Vol.24 (14), p.11419

2023

Volltextzugriff (PDF)

Genomic Mapping of Splicing-Related Genes Identify Amplifications in LSM1, CLNS1A, and ILF2 in Luminal Breast Cancer

Cancers, 2021-08, Vol.13 (16), p.4118

2021

Volltextzugriff (PDF)

Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study

Breast cancer research and treatment, 2010-07, Vol.122 (1), p.169-176

2010

Volltextzugriff (PDF)

1 – 25 von 132

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(130)
Mit Volltextzugriff
(111)

Publikationsform

Artikel
(132)

Sprache

Englisch
(132)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(125)
Humans
(95)
Oncology
(88)
Female
(87)
Breast Cancer
(59)
Middle Aged
(57)
Adult
(50)
Aged
(46)
Breast Neoplasms - Pathology
(37)
Breast Neoplasms - Drug Therapy
(33)
Chemotherapy
(25)
Medicine
(22)
Medicine & Public Health
(22)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(21)
Treatment Outcome
(21)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(20)
Tumors
(20)
Aged, 80 And Over
(19)
Breast Neoplasms - Genetics
(17)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families

Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy

Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study

A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study

Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine‐Induced Hand‐Foot Syndrome

Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3

Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor

XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease

Adoptive Cell Therapy in Breast Cancer: A Current Perspective of Next-Generation Medicine

Chemotherapy for gastric cancer

Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

A Polymorphism in the Cytidine Deaminase Promoter Predicts Severe Capecitabine-Induced Hand-Foot Syndrome

Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations

Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel: a study in locally advanced breast cancer patients participating in the NCT00123929 phase 2 randomized trial

CREditing: a tool for gene tuning in Trypanosoma cruzi

Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients

Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial

Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia

Effective gene delivery to Trypanosoma cruzi epimastigotes through nucleofection

Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study

Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors

Genomic Mapping of Splicing-Related Genes Identify Amplifications in LSM1, CLNS1A, and ILF2 in Luminal Breast Cancer

Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study

Aktive Filter

Suchergebnisse filtern